S&P 500 7,500.58 ▲ 80.48 (+1.08%) DOW 51,564.70 ▲ 72.15 (+0.14%) NASDAQ 26,517.93 ▲ 496.28 (+1.91%) US Markets Open â€ĸ 12:37 PM ET

SPRY

ARS Pharmaceuticals, Inc.

Price Chart
Latest Quote

$9.65

-0.25 (-2.53%)
Current Price
Previous Close $9.90
Open $10.05
Day High $10.25
Day Low $9.50
Volume 2,270,406
Fetched: 2026-06-19T16:37:28
Stock Information
Shares Outstanding 99.30M
Total Debt $171.20M
Cash Equivalents $200.97M
Revenue $98.99M
Net Income $-197.98M
Sector Healthcare
Industry Biotechnology
Market Cap $958.28M
EPS (TTM) $-2.00
Exchange NGM
🌐 Visit Website
📊 Comprehensive Analysis
Company Data
Enterprise Value$933.47M
Sales$98.99M
Income$-197.98M
Book/sh$1.15
Cash/sh$2.02
Employees154
Financial Ratios
Quick Ratio4.64
Current Ratio4.94
Debt/Eq279.24
Returns & Margins
ROA-41.15%
ROE-136.40%
Gross Margin59.41%
Operating Margin-265.18%
Profit Margin-200.00%
Ownership
Insider Ownership16.21%
Institutional Ownership95.47%
Insider & Institutional transactions data not available
Valuation Ratios
Forward P/E-10.08
P/S9.68
P/B8.38
Analyst Data
Recommendationnone
Target Price$28.80
Technical Indicators
SMA20$9.10
SMA50$8.56
SMA200$9.38
RSI57.29
ATR0.5794
Shares Float42.45M
Short Float37.04%
Short Ratio13.70
Volatility0.83
Rel Volume1.51
Performance History
Week+0.63%
Month+34.59%
Quarter+16.97%
6 Months-9.47%
YTD-16.01%
Year-34.89%
3 Years+52.93%
5 Years-70.96%
10 Years-61.40%
Stock Score: ⭐ Premium
Based on debt, profitability, growth, and cash flow metrics
⭐ Premium Feature

Sign up for free to view detailed scoring breakdown — premium is free during our trial period!

Recent Price History
Date Close Volume
2026-06-18 $9.65 2,278,000
2026-06-17 $9.90 1,018,600
2026-06-16 $9.70 874,800
2026-06-15 $9.81 1,049,300
2026-06-12 $9.76 1,324,300
2026-06-11 $9.59 989,800
2026-06-10 $9.26 1,481,400
2026-06-09 $9.41 877,500
2026-06-08 $8.99 1,909,500
2026-06-05 $8.56 1,289,200
2026-06-04 $9.07 817,500
2026-06-03 $8.75 1,209,400
2026-06-02 $8.90 1,853,300
2026-06-01 $9.43 1,973,300
2026-05-29 $9.07 2,149,400
2026-05-28 $9.40 2,607,400
2026-05-27 $8.50 794,200
2026-05-26 $8.17 1,059,700
2026-05-22 $7.94 2,486,000
2026-05-21 $8.23 2,126,700
2026-05-20 $7.80 1,625,600
2026-05-19 $7.17 1,604,300
About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

Period:
Loading...
Income Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Revenue
Reconciled Cost Of Revenue $20,423,000 $977,000 $0 -
Cost Of Revenue $20,423,000 $977,000 $0 -
Total Revenue $84,278,000 $89,149,000 $30,000 $1,316,000
Operating Revenue $84,278,000 $89,149,000 $30,000 $1,316,000
Expenses
Interest Expense $2,599,000 $0 - -
Total Expenses $263,726,000 $92,232,000 $67,550,000 $36,832,000
Net Non Operating Interest Income Expense $8,070,000 $11,369,000 - -
Interest Expense Non Operating $2,599,000 $0 - -
Operating Expense $243,303,000 $91,255,000 $67,550,000 $36,832,000
Other Income Expense - $11,369,000 $13,155,000 $834,000
Other Non Operating Income Expenses - $11,369,000 $13,155,000 $974,000
General And Administrative Expense - - $47,284,000 $18,456,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Net Interest Income $8,070,000 $11,369,000 - -
Interest Income $10,669,000 $11,369,000 - -
Normalized Income $-171,298,000 $7,998,000 $-54,365,000 $-34,542,000
Net Income From Continuing And Discontinued Operation $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Total Operating Income As Reported $-179,448,000 $-3,083,000 $-67,520,000 $-35,516,000
Net Income Common Stockholders $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Net Income $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Net Income Including Noncontrolling Interests $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Net Income Continuous Operations $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Pretax Income $-171,378,000 $8,286,000 $-54,365,000 $-34,682,000
Interest Income Non Operating $10,669,000 $11,369,000 - -
Operating Income $-179,448,000 $-3,083,000 $-67,520,000 $-35,516,000
Gross Profit $63,855,000 $88,172,000 $30,000 -
Per Share
Diluted EPS $-1.74 $0.08 $-0.57 $-0.87
Basic EPS $-1.74 $0.08 $-0.57 $-0.87
Other
Tax Effect Of Unusual Items $0 $0 $0 $0
Tax Rate For Calcs $0 $0 $0 $0
Normalized EBITDA (Bullshit earnings) $-168,779,000 $8,286,000 $-67,520,000 $-35,057,000
Reconciled Depreciation $-4,156,000 $-7,175,000 $-6,775,000 $319,000
EBITDA (Bullshit earnings) $-168,779,000 $8,286,000 $-67,520,000 $-35,197,000
EBIT $-168,779,000 $8,286,000 $-67,520,000 $-35,516,000
Diluted Average Shares $98,566,481 $102,390,828 $95,215,322 $39,956,043
Basic Average Shares $98,566,481 $96,936,661 $95,215,322 $39,956,043
Diluted NI Availto Com Stockholders $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Tax Provision $-80,000 $288,000 $0 -
Research And Development $13,181,000 $19,580,000 $20,266,000 $18,376,000
Selling General And Administration $230,122,000 $71,675,000 $47,284,000 $18,456,000
Other Gand A - - $47,284,000 $18,456,000
Total Unusual Items - - - $-140,000
Total Unusual Items Excluding Goodwill - - - $-140,000
Gain On Sale Of Security - - - $-140,000
Fetched: 2026-06-15
Balance Sheet (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Assets
Net Tangible Assets $99,806,000 $249,427,000 $230,143,000 $272,886,000
Total Assets $327,652,000 $351,153,000 $233,188,000 $281,435,000
Total Non Current Assets $42,756,000 $16,858,000 $1,462,000 $3,735,000
Other Non Current Assets $25,839,000 $8,421,000 - $2,961,000
Goodwill And Other Intangible Assets $14,452,000 $7,371,000 $617,000 $0
Other Intangible Assets $14,452,000 $7,371,000 $617,000 -
Current Assets $284,896,000 $334,295,000 $231,726,000 $277,700,000
Prepaid Assets $6,194,000 $6,886,000 $2,028,000 $2,310,000
Inventory $8,369,000 $5,212,000 $0 -
Receivables $25,347,000 $8,175,000 $686,000 $1,009,000
Accounts Receivable $25,347,000 $8,175,000 $0 -
Cash Cash Equivalents And Short Term Investments $244,986,000 $314,022,000 $228,360,000 $274,381,000
Cash And Cash Equivalents $41,317,000 $50,817,000 $70,971,000 $210,518,000
Non Current Prepaid Assets - $2,800,000 $21,000 $2,961,000
Other Current Assets - $1,232,000 $652,000 -
Accrued Interest Receivable - $987,000 $686,000 $796,000
Other Receivables - - $109,000 $213,000
Debt
Net Debt $55,057,000 - - -
Total Debt $96,374,000 $42,000 $274,000 $481,000
Long Term Debt And Capital Lease Obligation $96,374,000 $0 $37,000 $251,000
Long Term Debt $96,374,000 - - -
Current Debt And Capital Lease Obligation - $42,000 $237,000 $230,000
Current Debt - - - -
Liabilities
Total Liabilities Net Minority Interest $213,394,000 $94,355,000 $2,428,000 $8,549,000
Total Non Current Liabilities Net Minority Interest $174,249,000 $70,915,000 $37,000 $3,105,000
Other Non Current Liabilities $72,140,000 $69,383,000 - -
Non Current Deferred Liabilities $1,130,000 $1,532,000 $0 $2,854,000
Current Liabilities $39,145,000 $23,440,000 $2,391,000 $5,444,000
Other Current Liabilities $588,000 $42,000 - -
Current Deferred Liabilities $609,000 $557,000 $0 $283,000
Payables And Accrued Expenses $37,948,000 $22,841,000 $1,839,000 $4,484,000
Payables $5,725,000 $9,870,000 $759,000 $1,833,000
Accounts Payable $5,725,000 $9,870,000 $759,000 $1,659,000
Other Payable - - $155,000 $1,001,000
Total Tax Payable - - $4,000 $174,000
Derivative Product Liabilities - - - $0
Current Notes Payable - - - $0
Equity
Common Stock Equity $114,258,000 $256,798,000 $230,760,000 $272,886,000
Total Equity Gross Minority Interest $114,258,000 $256,798,000 $230,760,000 $272,886,000
Stockholders Equity $114,258,000 $256,798,000 $230,760,000 $272,886,000
Gains Losses Not Affecting Retained Earnings $125,000 $220,000 $49,000 $407,000
Other Equity Adjustments $125,000 $220,000 $49,000 $407,000
Retained Earnings $-294,603,000 $-123,305,000 $-131,303,000 $-76,938,000
Preferred Securities Outside Stock Equity - - - $0
Other
Ordinary Shares Number $99,290,926 $97,954,172 $96,414,963 $93,943,316
Share Issued $99,290,926 $97,954,172 $96,414,963 $93,943,316
Tangible Book Value $99,806,000 $249,427,000 $230,143,000 $272,886,000
Invested Capital $210,632,000 $256,798,000 $230,760,000 $272,886,000
Working Capital $245,751,000 $310,855,000 $229,335,000 $272,256,000
Total Capitalization $210,632,000 $256,798,000 $230,760,000 $272,886,000
Additional Paid In Capital $408,726,000 $379,873,000 $362,004,000 $349,408,000
Capital Stock $10,000 $10,000 $10,000 $9,000
Common Stock $10,000 $10,000 $10,000 $9,000
Preferred Stock $0 $0 $0 $0
Non Current Accrued Expenses $4,605,000 $0 - -
Non Current Deferred Revenue $1,130,000 $1,532,000 $0 $2,854,000
Current Deferred Revenue $609,000 $557,000 $0 $283,000
Current Accrued Expenses $32,223,000 $12,971,000 $1,080,000 $2,651,000
Net PPE $2,465,000 $1,066,000 $824,000 $774,000
Other Short Term Investments $203,669,000 $263,205,000 $157,389,000 $63,863,000
Capital Lease Obligations - $42,000 $274,000 $481,000
Long Term Capital Lease Obligation - $0 $37,000 $251,000
Current Capital Lease Obligation - $42,000 $237,000 $230,000
Pensionand Other Post Retirement Benefit Plans Current - $2,293,000 $315,000 $447,000
Accumulated Depreciation - $-200,000 $-121,000 $-48,000
Gross PPE - $1,266,000 $945,000 $822,000
Leases - $24,000 $24,000 -
Other Properties - $987,000 $840,000 $822,000
Machinery Furniture Equipment - $255,000 $81,000 -
Properties - $0 $0 -
Finished Goods - $5,212,000 $0 -
Fetched: 2026-06-15
Cash Flow Statement (Annual)
Metric 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Free Cash Flow
Free Cash Flow $-171,205,000 $12,985,000 $-59,441,000 $-40,277,000
Operating Activities
Operating Cash Flow $-170,866,000 $13,548,000 $-59,266,000 $-40,078,000
Cash Flow From Continuing Operating Activities $-170,866,000 $13,548,000 $-59,266,000 $-40,078,000
Operating Gains Losses - - - $140,000
Investing Activities
Capital Expenditure $-339,000 $-563,000 $-175,000 $-199,000
Investing Cash Flow $56,768,000 $-106,101,000 $-87,180,000 $-199,000
Cash Flow From Continuing Investing Activities $56,768,000 $-106,101,000 $-87,180,000 $-199,000
Net Other Investing Changes $-7,860,000 $-7,500,000 - -
Financing Activities
Financing Cash Flow $104,598,000 $72,399,000 $6,899,000 $190,732,000
Cash Flow From Continuing Financing Activities $104,598,000 $72,399,000 $6,899,000 $190,732,000
Net Other Financing Charges $2,660,000 $69,383,000 - $198,843,000
Issuance Of Capital Stock - - - $0
Net Preferred Stock Issuance - - - $0
Preferred Stock Issuance - - - $0
Other
Issuance Of Debt $96,257,000 $0 - -
Interest Paid Supplemental Data $2,452,000 $0 $0 $366,000
End Cash Position $41,317,000 $50,817,000 $70,971,000 $210,518,000
Beginning Cash Position $50,817,000 $70,971,000 $210,518,000 $60,063,000
Changes In Cash $-9,500,000 $-20,154,000 $-139,547,000 $150,455,000
Proceeds From Stock Option Exercised $5,681,000 $3,016,000 $6,899,000 $570,000
Net Issuance Payments Of Debt $96,257,000 $0 $0 $-8,681,000
Net Long Term Debt Issuance $96,257,000 $0 $0 $-8,681,000
Long Term Debt Issuance $96,257,000 $0 - -
Net Investment Purchase And Sale $64,967,000 $-98,038,000 $-87,005,000 $0
Sale Of Investment $307,000,000 $258,000,000 $185,000,000 $0
Purchase Of Investment $-242,033,000 $-356,038,000 $-272,005,000 $0
Net PPE Purchase And Sale $-339,000 $-563,000 $-175,000 $-199,000
Purchase Of PPE $-339,000 $-563,000 $-175,000 $-199,000
Change In Working Capital $-20,004,000 $-1,809,000 $-7,361,000 $-12,754,000
Change In Other Working Capital $-350,000 $2,089,000 $-3,149,000 $-1,283,000
Change In Payables And Accrued Expense $18,881,000 $16,413,000 $-2,777,000 $-10,285,000
Change In Prepaid Assets $656,000 $-6,191,000 $-1,435,000 $-1,186,000
Change In Inventory $-21,986,000 $-5,945,000 $0 -
Change In Receivables $-17,205,000 $-8,175,000 $0 -
Changes In Account Receivables $-17,205,000 $-8,175,000 $0 -
Other Non Cash Items $337,000 - - $1,056,000
Stock Based Compensation $22,095,000 $14,534,000 $9,235,000 $5,843,000
Provisionand Write Offof Assets $2,160,000 $0 - -
Depreciation Amortization Depletion $-4,156,000 $-7,175,000 $-6,775,000 $319,000
Depreciation And Amortization $-4,156,000 $-7,175,000 $-6,775,000 $319,000
Amortization Cash Flow $-5,523,000 $-7,254,000 $-6,848,000 $285,000
Amortization Of Intangibles $-5,523,000 $-7,254,000 $-6,848,000 $285,000
Depreciation $1,367,000 $79,000 $73,000 $34,000
Net Income From Continuing Operations $-171,298,000 $7,998,000 $-54,365,000 $-34,682,000
Repayment Of Debt - - $0 $-8,681,000
Long Term Debt Payments - - $0 $-8,681,000
Gain Loss On Investment Securities - - - $140,000
Change In Other Current Assets - - - -
Fetched: 2026-06-15